LIPELLA PHARMACEUTICALS INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7551 USD | -0.96% |
|
+3.16% | -25.97% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 5.92 | 5.799 | - | - |
| Enterprise Value (EV) 1 | 5.92 | 5.799 | 5.799 | 5.799 |
| P/E ratio | -1.32 x | -2.82 x | -3.31 x | -3.05 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | -1.71 x | -1.14 x | -0.76 x |
| FCF Yield | - | -58.6% | -88% | -132% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 5,804 | 7,606 | - | - |
| Reference price 2 | 1.020 | 0.7624 | 0.7624 | 0.7624 |
| Announcement Date | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | - | -3.4 | -5.1 | -7.65 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -3.4 | -5.1 | -7.65 |
| Net income 1 | -4.619 | -3.4 | -5.1 | -7.65 |
| Net margin | - | - | - | - |
| EPS 2 | -0.7700 | -0.2700 | -0.2300 | -0.2500 |
| Free Cash Flow 1 | - | -3.4 | -5.1 | -7.65 |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | -3.4 | -5.1 | -7.65 |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 2/27/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.7624
USD
Average target price
2
USD
Spread / Average Target
+162.32%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -25.97% | 5.8M | |
| +9.32% | 114B | |
| +11.41% | 104B | |
| -13.90% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.29% | 17.89B | |
| +7.60% | 14.28B | |
| +34.78% | 12.55B |
- Stock Market
- Equities
- LIPO Stock
- Financials Lipella Pharmaceuticals Inc.
